WHICH PREMIUM IOL IS BEST?

This study in the Journal of Cataract and Refractive Surgery compares various premium intraocular implants for near vision.   It concludes:

Multifocal IOLs with a diffractive component provided good reading performance that was significantly better than that obtained with a refractive multifocal or monofocal IOL.

OCRIPLASMIN APPROVED TO TREAT VITREORETINAL ADHESION

This report in Reuters announces the approval of Ocriplasmin,

"for treatment of symptomatic vitreomacular adhesion - an aging-related pulling on the retina" 

NEW TREATMENT FOR AMD?

This report introduces a study designed to evaluate the safety and efficacy of purified human neural stem cells (HuCNS-SC, StemCells Inc.), as a treatment for dry age-related macular degeneration (AMD). 

RETINAL ARTERY OCCLUSION IS A POSSIBLE COMPLICATION OF FACIAL FILLERS

According to this study in the American Journal of Ophthalmology:

Cosmetic filler injections into the glabellar region or nasolabial fold can cause retinal artery occlusion. Iatrogenic ophthalmic artery occlusion is associated with painful blindness, a thin choroid, brain infarction, and poor visual outcomes, particularly when autologous fat is used. Ophthalmic examination and systematic brain magnetic resonance imaging should be performed in patients with ocular pain after such injections.

COFFEE INCREASES RISK FOR EXFOLIATIVE GLAUCOMA

According to this report in Healthday:

drinking three or more cups of caffeinated coffee was found to be associated with increased risk of developing exfoliation glaucoma, particularly among those with a family history of glaucoma

CENTRAL SEROUS RETINOPATHY ASSOCIATED WITH ERECTILE DYSFUNCTION

This study in Acta Ophthalmologica concludes:

Central serous chorioretinopathy was independently associated with an increased risk of being diagnosed with erectile dysfunction.

STATINS HELP IN GLAUCOMA

This report in The Telegraph quotes:

Scientists found the risk of developing glaucoma was eight per cent lower among those who took statins for at least two years, compared to those who did not take them.

XEAXANTHIN AND LUTEIN SUPPLEMENTATION GOOD IN EARLY MACULAR DEGENERATION

This study in the American Journal of Ophthalmology concludes:

Early functional abnormalities of the central retina in the early AMD patients could be improved by lutein and zeaxanthin supplementation